ToplineA panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly’s experimental Alzheimer’s drug donanemab for FDA approval, a closely watched decision that could pave the way for the drug to become the second of its kind authorized in the U.S..Experts are weighing up donanemab, Eli Lilly's Alzheimer's drug. getty Key FactsThe Peripheral and Central Nervous System Drugs Advisory Committee will meet on Monday to consider whether the benefits of Lilly’s drug outweigh its ...

One of the most lucrative sports sponsorship opportunities is jersey patches, and one leading pharmaceutical company may have just struck gold.When it comes to the business of sports, brand sponsorships are a commonly used strategy. This makes sense, as many athletes tend to become synonymous with certain companies.It's nearly impossible not to think of Nike when you see Michael Jordan or Serena Williams. Or what about insurance company State Farm? Perhaps Patrick Mahomes comes to mind.In May, pharmaceutica ...

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of MedicineINDIANAPOLIS, June 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or ...

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images)NurPhoto via Getty ImagesEli Lilly stock (NYSE: LLY) has seen phenomenal gains of 400% from levels of $170 in early 2021 to around $840 now. This reflects a meaningful outperformance compared to some of its peers, with Pfizer stock (NYSE: PFE) seeing a 15% decline and Johnson & Johnson stock (NYSE: JNJ) seeing no gains over the same period. This sig ...

The weight loss drug market is growing rapidly.Eli Lilly (LLY 0.67%) shares have soared more than 87% over the past year, making this player look more like a growth stock than a slower-paced but steady pharmaceutical stock. Lilly sells a broad range of medicines, but what lately has struck the fancy of investors -- and doctors and patients -- is the company's weight loss portfolio.Doctors prescribe Lilly's Mounjaro and Zepbound to help patients manage their weight, and the results have been fantastic. This ...

Eli Lilly and Company (LLY) announced that its executive vice president and chief financial officer (CFO) Anat Ashkenazi has resigned after serving for 23 years at the company. Ashkenazi has joined Google’s parent company Alphabet (GOOGL) as CFO and senior vice president, effective Jul 31, 2024. Until then, she will continue to serve in her present role at Lilly.Until Ashkenazi joins in her new role as CFO of Google and Alphabet, Ruth Porat, the present CFO of Alphabet will continue as CFO. In July last yea ...

INDIANAPOLIS, June 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. "On behalf of our board of directors, leadership team and employees, I would like to thank Anat for her 23 years of outstanding service to our company," said David A. Ricks, Lilly's chair and CEO. "During her last three years as Lilly's CFO, we have experienced tremendous growth and laid ...

Eli Lilly and Company (NYSE:LLY) Lilly Oncology ASCO Investor Event June 2, 2024 8:30 PM ET Company Participants Jake Van Naarden - Executive VP & President of Loxo Lillian Smyth - Senior Vice President and Global Development Head for Breast Cancer at Loxo John Pagel - Vice President and Head of Global Hematology at Loxo Geoff Oxnard - VP of Clinical Development, Global Head Thoracic Cancer at Loxo Arjun Balar - MD, Vice President, Global Clinical Development at Loxo Barry Taylor - Chief Scientific Officer ...

Key Points **Industry/Company Involved**: * Eli Lilly and Company (NYSE:LLY) * Lilly Oncology **Core Points and Arguments**: 1. **Oncology Strategy and Portfolio Modernization**: Lilly has been working to modernize its oncology portfolio and strategy over the past couple of years. This includes a focus on biology, target selection, and building the right medicines. [5] 2. **Acquisition of Loxo**: Lilly acquired Loxo in 2019, bringing in a new team and a new approach to oncology drug development. [7] 3. **Pipeline and Pipeline Efficiency**: Lilly has terminated nearly the entire pipeline and started from scratch, focusing on building a pipeline with a higher probability of delivering successful medicines. [14] 4. **Diversification of Modalities**: Lilly has diversified its drug development approach, including small molecules, antibody drug conjugates, T-cell redirectors, and radioligand therapies. [16] 5. **Clinical Trial Enrollment Bottleneck**: Clinical trial enrollment remains a significant bottleneck in drug development. Lilly has initiated efforts to improve clinical trial access for patients. [23] 6. **Commercial Performance**: Lilly's oncology portfolio has seen robust growth, particularly with key growth brands like Verzenio, Retevmo, and Jaypirca. [19] 7. **Investigational Portfolio**: Lilly has a strong investigational portfolio, including new molecules and combinations targeting various cancer types. [24] 8. **Precision Medicine**: Lilly is focused on bringing precision medicine to larger populations, making a bigger impact on cancer care. [86] **Other Important Points**: 1. **KRAS G12C Inhibitors**: Lilly has a strong KRAS G12C inhibitor program, including olomorasib, targeting first-line lung cancer. [54] 2. **Jaypirca**: Jaypirca, a Bruton's tyrosine kinase inhibitor, has been approved for relapsed mantle cell lymphoma and CLL. [43] 3. **LOXO-435**: LOXO-435, an isoform-selective FGFR3 inhibitor, is being developed for metastatic urothelial cancer. [64] 4. **Nectin-4 Targeted ADCs**: Nectin-4 targeted ADCs are being developed for metastatic urothelial cancer. [64] 5. **SMARCA2 Selective Inhibitor**: A selective SMARCA2 selective inhibitor program is being developed in collaboration with Foghorn Therapeutics. [75] 6. **Radioligand Therapy**: Lilly has entered the radioligand therapy space with the acquisition of POINT Biopharma and partnerships with Aktis Oncology. [79] **Data and Percentages**: * 60% of eligible patients with high-risk early breast cancer are receiving Verzenio. [20] * 15% of breast cancer cases have H1047R mutations. [39] * 15-20% of patients with advanced urothelial cancer have FGFR alterations. [65] * 10% of lung cancer cases have SMARCA4 mutations. [75]

The fight for dominance in the weight loss market is just getting started.Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss therapies have become the industry's versions of rock stars, and none is more popular than Novo Nordisk's Wegovy.Other companies are looking to challenge the Denmark-based drugmaker. Its longtime rival in the diabetes market, Eli Lilly (LLY 0.75%), recently launched a competing anti-obesity medicine called tirzepatide, ...